Cargando…

Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy

Immunotherapy has gradually become an emerging treatment modality for tumors after surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for cancer immunotherapy. Currently, there are many preclinical theoretical bases to support this treatment strategy and a variety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Heping, Ma, Shuang, Zhao, Duoyi, Zhao, Wei, Cui, Yan, Hua, Yingqi, Zhang, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788370/
https://www.ncbi.nlm.nih.gov/pubmed/36559100
http://dx.doi.org/10.3390/pharmaceutics14122606
_version_ 1784858737993842688
author Lian, Heping
Ma, Shuang
Zhao, Duoyi
Zhao, Wei
Cui, Yan
Hua, Yingqi
Zhang, Zhiyu
author_facet Lian, Heping
Ma, Shuang
Zhao, Duoyi
Zhao, Wei
Cui, Yan
Hua, Yingqi
Zhang, Zhiyu
author_sort Lian, Heping
collection PubMed
description Immunotherapy has gradually become an emerging treatment modality for tumors after surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for cancer immunotherapy. Currently, there are many preclinical theoretical bases to support this treatment strategy and a variety of cytokines in clinical trials. When cytokines were applied to tumor immunotherapy, it was found that the efficacy was not satisfactory. As research on tumor immunity has deepened, the role of cytokines in the tumor microenvironment has been further explored. Meanwhile, the study of nanomaterials in drug delivery has been fully developed in the past 20 years. Researchers have begun to think about the possibility of combining cytokine therapy with nanomaterials. Herein, we briefly review various nano-delivery systems that can directly deliver cytokines or regulate the expression of cytokines in tumor cells for cancer immunotherapy. We further discussed the feasibility of the combination of various therapies. We looked forward to the main challenges, opportunities, and prospects of tumor immunotherapy with multiple cytokines and a nano-delivery system.
format Online
Article
Text
id pubmed-9788370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97883702022-12-24 Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy Lian, Heping Ma, Shuang Zhao, Duoyi Zhao, Wei Cui, Yan Hua, Yingqi Zhang, Zhiyu Pharmaceutics Review Immunotherapy has gradually become an emerging treatment modality for tumors after surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for cancer immunotherapy. Currently, there are many preclinical theoretical bases to support this treatment strategy and a variety of cytokines in clinical trials. When cytokines were applied to tumor immunotherapy, it was found that the efficacy was not satisfactory. As research on tumor immunity has deepened, the role of cytokines in the tumor microenvironment has been further explored. Meanwhile, the study of nanomaterials in drug delivery has been fully developed in the past 20 years. Researchers have begun to think about the possibility of combining cytokine therapy with nanomaterials. Herein, we briefly review various nano-delivery systems that can directly deliver cytokines or regulate the expression of cytokines in tumor cells for cancer immunotherapy. We further discussed the feasibility of the combination of various therapies. We looked forward to the main challenges, opportunities, and prospects of tumor immunotherapy with multiple cytokines and a nano-delivery system. MDPI 2022-11-26 /pmc/articles/PMC9788370/ /pubmed/36559100 http://dx.doi.org/10.3390/pharmaceutics14122606 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lian, Heping
Ma, Shuang
Zhao, Duoyi
Zhao, Wei
Cui, Yan
Hua, Yingqi
Zhang, Zhiyu
Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
title Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
title_full Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
title_fullStr Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
title_full_unstemmed Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
title_short Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
title_sort cytokine therapy combined with nanomaterials participates in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788370/
https://www.ncbi.nlm.nih.gov/pubmed/36559100
http://dx.doi.org/10.3390/pharmaceutics14122606
work_keys_str_mv AT lianheping cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy
AT mashuang cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy
AT zhaoduoyi cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy
AT zhaowei cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy
AT cuiyan cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy
AT huayingqi cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy
AT zhangzhiyu cytokinetherapycombinedwithnanomaterialsparticipatesincancerimmunotherapy